• TransMedics Group (TMDX) is trading at $77.64 (5.2% up) as it draws fresh attention from a recent share price swing.
  • A June 24, 2026 analysis suggests TMDX is 33.2% undervalued, with a fair value closer to $117.89.
  • Growth plans include expansion into new organ types (kidney) and next-generation product launches (Gen 3 OCS platforms for heart, lung, and liver), expected to grow its total addressable market and improve product mix.